---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-000648"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2024-02-07T23:59:59+00:00"
generated_at: "2026-06-06T06:23:46.701549+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "medium"
source: SEC EDGAR
---

# Cassava Sciences: simufilam shows stable ADAS-Cog in mild Alzheimer's over 24 months

## Summary
- Mild Alzheimer's patients on continuous simufilam (n=47) averaged 0.07 point ADAS-Cog change (±1.51 SE) from baseline to month 24.
- Non-continuous mild group (n=40) declined 1.04 points on ADAS-Cog (±1.65 SE); largest separation during placebo withdrawal.
- Moderate Alzheimer's patients on continuous simufilam (n=32) declined 11.05 points on ADAS-Cog (±1.91 SE).
- Simufilam 100 mg twice daily safe and well tolerated; no drug-related serious adverse events; common TEAEs were COVID-19 and UTI.
- Phase 3 top-line results expected: 52-week study year-end 2024; 76-week study mid-2025.

## SEC filing metadata
- accession: 0001171843-24-000648
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2024-02-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000117184324000648/0001171843-24-000648-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000117184324000648/f8k_020724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-000648
- JSON: https://secwatch.observer/filing/0001171843-24-000648.json
- Plain text: https://secwatch.observer/filing/0001171843-24-000648.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.